Rady M Y, Ryan T
Department of Cardiothoracic Anesthesia, Cleveland Clinic Foundation, USA.
Chest. 1998 Aug;114(2):487-94. doi: 10.1378/chest.114.2.487.
To determine the effect of preoperative therapy with angiotensin-converting enzyme (ACE) inhibitors on clinical outcome after cardiovascular surgery.
Inception cohort.
A tertiary care 54-bed cardiothoracic ICU.
All admissions to an ICU over a 42-month period after cardiovascular surgery.
Extraction of preoperative, operative, and ICU data from a database.
Incidence of acute organ dysfunction, length of mechanical ventilation, ICU stay, and death after cardiovascular surgery.
The study cohort consisted of four groups: normal or moderately impaired left ventricular function control (group A, n=6,400); normal or moderately impaired left ventricular function treated with ACE inhibitors (group B, n=1,375); severe left ventricular dysfunction control (group C, n=1,905); and severe left ventricular dysfunction treated with ACE inhibitors (group D, n=1,650). The incidence of three or more organ dysfunction was similar on comparison of group A vs group B (5% vs 6%) or group C vs group D (15% vs 13%). There were no differences in the total duration of mechanical ventilation or length of stay in the ICU in group A vs group B or group C vs group D. Death occurred in 2% of groups A and B, and at 6% in groups C and D. Preoperative severe left ventricular dysfunction in both groups C and D was associated with an increased incidence of three or more organ dysfunction, duration of mechanical ventilation, length of stay in ICU, and death after surgery. Multivariate analysis indicated that therapy with ACE inhibitors did not affect the clinical outcome after cardiovascular surgery.
Preoperative therapy with ACE inhibitors did not influence the clinical outcome after cardiac surgery. It is unlikely that therapy with ACE inhibitors can alter the clinical sequelae of cardiopulmonary bypass and cardiac surgical procedures performed in high-risk patients because of underlying severe left ventricular dysfunction.
确定血管紧张素转换酶(ACE)抑制剂术前治疗对心血管手术后临床结局的影响。
起始队列研究。
一家拥有54张床位的三级医疗心胸重症监护病房。
心血管手术后42个月期间入住重症监护病房的所有患者。
从数据库中提取术前、手术及重症监护病房数据。
心血管手术后急性器官功能障碍的发生率、机械通气时间、重症监护病房住院时间及死亡率。
研究队列包括四组:左心室功能正常或轻度受损的对照组(A组,n = 6400);接受ACE抑制剂治疗的左心室功能正常或轻度受损组(B组,n = 1375);严重左心室功能障碍对照组(C组,n = 1905);接受ACE抑制剂治疗的严重左心室功能障碍组(D组,n = 1650)。比较A组与B组(5%对6%)或C组与D组(15%对13%)时,三个或更多器官功能障碍的发生率相似。A组与B组或C组与D组在机械通气总时长或重症监护病房住院时长方面无差异。A组和B组的死亡率为2%,C组和D组为6%。C组和D组术前严重左心室功能障碍与三个或更多器官功能障碍的发生率增加、机械通气时长、重症监护病房住院时长及术后死亡率相关。多因素分析表明,ACE抑制剂治疗不影响心血管手术后的临床结局。
ACE抑制剂术前治疗不影响心脏手术后的临床结局。由于潜在的严重左心室功能障碍,ACE抑制剂治疗不太可能改变高危患者体外循环和心脏手术操作的临床后遗症。